Testosterone deficiency and the aging male

Int J Impot Res. 2022 Nov;34(7):630-634. doi: 10.1038/s41443-022-00555-7. Epub 2022 Apr 7.

Abstract

Testosterone deficiency (TD), also known as male hypogonadism, is a complex syndrome encompassing physical, biochemical, and social aspects that increasingly affects the aging population. TD has been analyzed over recent decades, with an enhanced focus on etiologies relating to aging males. There is debate whether testosterone decline leading to hypogonadism is directly and primarily related to age-specific processes or if it is the subsequent result of accumulating comorbidities throughout a lifetime. Several studies have been done to further characterize this distinction. Chronic comorbidities that have commonly been associated with TD include hypertension (HTN), cardiovascular disease (CVD), diabetes mellitus (DM), obesity, metabolic syndrome (MetS), chronic kidney disease (CKD), and tobacco use. Although clear associations between hypogonadism and aging have been biochemically demonstrated, many large studies have illustrated the concomitant effects of highly prevalent chronic diseases and social behaviors in aging men. Given the significant impact of hypogonadism on the physical and mental health of men, this paper aims to delve into these studies and further define the complex relationship of testosterone deficiency in the aging male.

Publication types

  • Review

MeSH terms

  • Aged
  • Aging
  • Humans
  • Hypogonadism* / complications
  • Male
  • Metabolic Syndrome* / complications
  • Metabolic Syndrome* / epidemiology
  • Obesity / complications
  • Testosterone

Substances

  • Testosterone